Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Hunter, VJ, Daly, L, Helms, M, Soper, JT, Berchuck, A, Clarke-Pearson, DL, and Jr, RCB. "The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction." American Journal of Obstetrics and Gynecology 163, no. 4 PART 1 (1990): 1164-1167.

Scholars@Duke

Berchuck, A, Rubin, SC, Hoskins, WJ, Saigo, PE, Pierce, VK, and Lewis, JL. "Treatment of endometrial stromal tumors." Gynecol Oncol 36, no. 1 (January 1990): 60-65.

Scholars@Duke

Berchuck, A, Soisson, AP, Olt, GJ, Soper, JT, Clarke-Pearson, DL, Bast, RC, and McCarty, KS. "Epidermal growth factor receptor expression in normal and malignant endometrium." Am J Obstet Gynecol 161, no. 5 (November 1989): 1247-1252.

Scholars@Duke

Soisson, AP, Berchuck, A, Lessey, BA, Soper, JT, Clarke-Pearson, DL, McCarty, KS, and Bast, RC. "Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels." Am J Obstet Gynecol 161, no. 5 (November 1989): 1258-1263.

Scholars@Duke

Soper, JT, Larson, D, Hunter, VJ, Berchuck, A, and Clarke-Pearson, DL. "Short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery." Obstet Gynecol 74, no. 5 (November 1989): 823-827.

Scholars@Duke

Soper, JT, Berchuck, A, Creasman, WT, and Clarke-Pearson, DL. "Pelvic exenteration: factors associated with major surgical morbidity." Gynecol Oncol 35, no. 1 (October 1989): 93-98.

Scholars@Duke

Berchuck, A, Soisson, AP, Soper, JT, Clarke-Pearson, DL, Bast, RC, and McCarty, KS. "Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues." Arch Pathol Lab Med 113, no. 10 (October 1989): 1155-1158.

Scholars@Duke

Berchuck, A, MacDonald, PC, Milewich, L, and Casey, ML. "Transforming growth factor-beta inhibits prostaglandin production in amnion and A431 cells." Prostaglandins 38, no. 4 (October 1989): 453-464.

Scholars@Duke

Massad, LS, Santoriello, K, and Berchuck, A. "Pneumoperitoneum due to peritoneovaginal fistula following hysterectomy." Int J Gynaecol Obstet 29, no. 3 (July 1989): 257-261. (Review)

Scholars@Duke

Berchuck, A, Soisson, AP, Clarke-Pearson, DL, Soper, JT, Boyer, CM, Kinney, RB, McCarty, KS, and Bast, RC. "Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential." Cancer Res 49, no. 8 (April 15, 1989): 2091-2095.

Scholars@Duke

Pages